Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Dianthus Therapeutics, Inc. - Common Stock
(NQ:
DNTH
)
87.39
-2.43 (-2.71%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 24, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Dianthus Therapeutics, Inc. - Common Stock
< Previous
1
2
Next >
Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000
↗
April 19, 2026
This clinical-stage biotech focused on monoclonal antibody therapies reported a notable insider sale in its latest SEC filing.
Via
The Motley Fool
Topics
Regulatory Compliance
Dianthus Therapeutics CFO Sells $9.5 Million in Stock
↗
April 06, 2026
This biotech firm developing antibody therapies for rare diseases disclosed a significant insider sale amid rapid share price gains.
Via
The Motley Fool
Topics
Regulatory Compliance
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit
↗
March 18, 2026
Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions.
Via
The Motley Fool
Forecasting The Future: 5 Analyst Projections For Dianthus Therapeutics
↗
December 20, 2024
Via
Benzinga
Evaluating Dianthus Therapeutics: Insights From 5 Financial Analysts
↗
November 11, 2024
Via
Benzinga
A Glimpse Into The Expert Outlook On Dianthus Therapeutics Through 4 Analysts
↗
November 08, 2024
Via
Benzinga
Complementing the Future: A Deep Dive into Dianthus Therapeutics (DNTH) After Its Phase 3 Breakthrough
March 12, 2026
Date: March 12, 2026 Introduction Dianthus Therapeutics (NASDAQ: DNTH) has become the center of Wall Street’s attention today, with its share price surging 19.4% in early trading following a pivotal...
Via
Finterra
Topics
Economy
DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch
↗
March 09, 2026
Dianthus Therapeutics announced an early “go” decision for its experimental drug claseprubart in its Chronic Inflammatory Demyelinating Polyneuropathy program based on analysis of data from a part of...
Via
Stocktwits
Gapping stocks in Monday's session
↗
March 09, 2026
Via
Chartmill
Expert Ratings For Dianthus Therapeutics
↗
September 26, 2024
Via
Benzinga
Navigating 4 Analyst Ratings For Dianthus Therapeutics
↗
August 12, 2024
Via
Benzinga
What 5 Analyst Ratings Have To Say About Dianthus Therapeutics
↗
May 10, 2024
Via
Benzinga
The Great Rotation: Small-Caps Break the Mega-Cap Monopoly in Early 2026
February 23, 2026
The financial landscape of 2026 has opened with a dramatic shift in market leadership, as small-cap stocks stage a historic rally that has left large-cap tech giants in the rearview mirror. After years...
Via
MarketMinute
Topics
Artificial Intelligence
Earnings
Economy
Dianthus CFO Sells 20,000 Shares for $903,600 After Massive Year-End Run
↗
January 07, 2026
This biotech developing therapies for rare autoimmune diseases reported notable insider selling in its most recent SEC disclosure.
Via
The Motley Fool
Topics
Regulatory Compliance
General Motors To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Friday
↗
September 12, 2025
Via
Benzinga
3 Biotech Stocks Showing Strength With Big Spikes In Momentum Scores
↗
September 12, 2025
A handful of biotech stocks are showing renewed strength, with big spikes in their Benzinga Edge Ranking's Momentum scores.
Via
Benzinga
Analyst Expectations For Dianthus Therapeutics's Future
↗
September 09, 2025
Via
Benzinga
Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again
↗
September 08, 2025
The company is working on a treatment for an autoimmune disease that affects the muscles.
Via
Investor's Business Daily
Dianthus Scores Early Success, Analyst Boosts Confidence In Broader Drug Pipeline
↗
September 08, 2025
Dianthus's claseprubart showed rapid, meaningful improvements in gMG symptoms with a favorable safety profile in Phase 2 MaGic trial results.
Via
Benzinga
Top movers in Monday's pre-market session
↗
September 08, 2025
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Via
Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
September 08, 2025
Via
Benzinga
Dianthus Therapeutics Inc (NASDAQ:DNTH) Q2 2025 Earnings: Revenue Misses, EPS Meets Estimates
↗
August 07, 2025
Dianthus Therapeutics Q2 2025 earnings show revenue miss but EPS in line. Cash reserves strong, key clinical trials progressing with major data readouts expected in 2025-2026.
Via
Chartmill
Dianthus (DNTH) Q2 Loss Widens 80%
↗
August 07, 2025
Via
The Motley Fool
Breaking Down Dianthus Therapeutics: 5 Analysts Share Their Views
↗
May 13, 2025
Via
Benzinga
Friday's pre-market session: top gainers and losers
↗
April 04, 2025
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Via
Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
April 04, 2025
Via
Benzinga
Powell Industries Reports Weak Sales, Joins Target, QuidelOrtho And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
↗
November 20, 2024
Via
Benzinga
Ulta Beauty Reports Downbeat Results, Joins Elastic And Other Big Stocks Moving Lower In Friday's Pre-Market Session
↗
August 30, 2024
Via
Benzinga
DNTH Stock Earnings: Dianthus Therapeutics Beats EPS, Beats Revenue for Q2 2024
↗
August 09, 2024
DNTH stock results show that Dianthus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
DNTH Stock Earnings: Dianthus Therapeutics Misses EPS, Beats Revenue for Q1 2024
↗
May 09, 2024
DNTH stock results show that Dianthus Therapeutics missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Via
InvestorPlace
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
